Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors

Abstract The fibroblast growth factor receptor (FGFR) is a crucial receptor tyrosine kinase involved in essential biological processes, including growth, development, and tissue repair. However, FGFR gene mutations, including amplification, fusion, and mutation, can disrupt epigenetics, transcriptional regulation, and tumor microenvironment interactions, leading to cancer development. Targeting these kinase mutations with small molecule drugs or antibodies has shown clinical benefits. For example, erdafitinib is approved for treating locally advanced or metastatic urothelial cancer patients with FGFR2/FGFR3 mutations, and pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement. Effective screening of FGFR variant patients is crucial for the clinical application of FGFR inhibitors. Various detection methods, such as polymerase chain reaction, next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry, are available, and their selection should be based on diagnostic and treatment decision-making needs. Our developed expert consensus aims to standardize the diagnosis and treatment process for FGFR gene mutations and facilitate the practical application of FGFR inhibitors in clinical practice.

• Publication year

  2024

• Venue

  Global Medical Genetics

• Publication date

  2024-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0044-1790230PMID 39583123PMCID 11405117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

  2023cited by this paper
• Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.

  2023cited by this paper
• Evaluation of FGFR Alteration Status in Urothelial Tumors.

  2023cited by this paper
• Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.

  2023cited by this paper
• Abstract CT016: Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study

  2023cited by this paper
• Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

  2022cited by this paper
• Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.

  2022cited by this paper
• Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

  2022cited by this paper
• FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures

  2022cited by this paper
• Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

  2021cited by this paper
• Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing

  2021cited by this paper
• Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

  2021cited by this paper
• Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

  2020cited by this paper
• Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients

  2020cited by this paper
• Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

  2020cited by this paper
• Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

  2019cited by this paper
• Erdafitinib in Urothelial Carcinoma.

  2019cited by this paper
• Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

  2019cited by this paper
• Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient

  2017cited by this paper
• A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

  2017cited by this paper
• Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

  2017cited by this paper
• A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification

  2017cited by this paper
• Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment

  2016cited by this paper
• FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival

  2016cited by this paper
• Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

  2016cited by this paper
• Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors

  2016cited by this paper
• Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients

  2016cited by this paper
• FGFR3 unliganded dimer stabilization by the juxtamembrane domain.

  2015cited by this paper
• FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies

  2015cited by this paper
• Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

  2015cited by this paper
• Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.

  2015cited by this paper
• The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

  2015cited by this paper
• Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

  2015cited by this paper
• Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.

  2014cited by this paper
• New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

  2014cited by this paper
• Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.

  2014cited by this paper
• Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

  2014cited by this paper
• Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.

  2014cited by this paper
• Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma

  2014cited by this paper
• FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

  2014cited by this paper
• Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

  2014cited by this paper
• Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

  2014cited by this paper
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

  2014cited by this paper
• Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

  2013cited by this paper
• FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

  2013cited by this paper
• Identification of targetable FGFR gene fusions in diverse cancers.

  2013cited by this paper
• Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling

  2013cited by this paper
• The transcriptional landscape and mutational profile of lung adenocarcinoma

  2012cited by this paper
• Anticancer molecules targeting fibroblast growth factor receptors.

  2012cited by this paper
• Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

  2012cited by this paper
• Oncogenic FGFR3 gene fusions in bladder cancer

  2012cited by this paper
• Dissecting the genomic complexity underlying medulloblastoma

  2012cited by this paper
• Crouzon's syndrome: A review of literature and case report

  2011cited by this paper
• FOXO1–FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma

  2011cited by this paper
• A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.

  2011cited by this paper
• FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

  2010cited by this paper
• Fibroblast growth factor signalling: from development to cancer

  2010cited by this paper
• Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors

  2009cited by this paper
• [Breast cancer].

  2006cited by this paper
• Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.

  2005cited by this paper
• Mechanisms underlying differential responses to FGF signaling.

  2005cited by this paper
• Cellular signaling by fibroblast growth factor receptors.

  2005cited by this paper
• Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations.

  2005cited by this paper
• Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.

  1999cited by this paper
• Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

  1996cited by this paper
• Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.

  1996cited by this paper
• Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia

  1994cited by this paper
• Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome

  1994cited by this paper
• [The medical school].

  1977cited by this paper

• Ligand-Based Computational Design and Preclinical Evaluation of a Novel Cyclic Peptide Radiotracer for FGFR1-Targeted PET Imaging in Uveal Melanoma.

  2026cites this paper
• FGFR-Driven Lung Cancer: Dissecting Resistance and Exploring Therapeutic Avenues.

  2026cites this paper
• ECLUNG Consensus/Guidelines Development Principles and Methods (2024 Edition)

  2025cites this paper
• Current insights and barriers in FGFR-mediated signaling in lung cancer.

  2025cites this paper
• From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology

  2025cites this paper
• Precision Oncology Guided by Genomic Profiling in Breast Cancer: Real-World Data from a Molecular Tumor Board

  2025cites this paper